LTS announced today that it will support Micron Biomedical, Inc. as selected CDMO partner in the manufacturing scale-up of Micron´s Microarray Patch technology.
After more than 45 years at LTS, of which 8 as Board Member, Michael Hoffmann will retire from LTS on 31 December 2023. The position of Chief Operating Officer will be taken over by Dr. Claudia Schaefer as of 01.01.2024.
The agreement is for a proprietary (S)-ketamine formulation, administered sub-lingually via an oral thin film (OTF) and Awakn will have global exclusivity of its use for Treatment of Addiction, Anxiety Disorders, and Eating Disorders.
Grant for the support the development of MAP for self-administration of contraceptives for women in low- and middle-income countries (LMICs)
LTS has received a grant from the Bill & Melinda Gates Foundation for support new formulation methods for mRNA.
LTS hands over donations of € 60,000 to the Hoffnungswerk and the Koblenz Hospice Association
Watch our webcast with Greg Moakes talking about “The LTS SorrelTM Platform – Solving Dilemmas in the fill/finish process”.
Leading pharmatech unifies quality processes for greater efficiency, collaboration, and compliance
When it comes to the take up of innovative technologies, early adoption is always a double-edged sword. Conceivably, there are greater risks involved, but there are also undoubtedly greater rewards on offer.
LTS has completed its acquisition of the Sorrel wearable injection device business with headquarters in Netanya, Israel, from Eitan Medical Ltd.
